阿托伐他汀联合肠溶阿司匹林对颈动脉粥样硬化患者血清TNF-α、IL-6水平的影响

Influence of atorvastatin combining with enteric-coated aspirin on serum TNF-α,IL-6 levels in patients with carotid atherosclerosis

目的:观察阿托伐他汀联合肠溶阿司匹林对颈动脉粥样硬化患者颈动脉粥样硬化程度和血清肿瘤坏死因子α(TNF-α)、白细胞介素-6(IL-6)水平的影响。方法:将125例颈动脉粥样硬化患者随机分为两组,治疗组64例,对照组61例,对照组口服阿托伐他汀,治疗组口服阿托伐他汀联合肠溶阿司匹林,治疗6个月后观察两组患者颈动脉粥样硬化程度和血清TNF-αI、L-6水平的变化。结果:与治疗前比较,两组治疗后颈动脉平均斑块数量、颈动脉管腔直径、平均斑块面积和血清TNF-αI、L-6含量明显降低(P<0.01);与对照组比较,治疗组治疗后颈动脉平均斑块数量、平均斑块面积以及血清TNF-α含量均显著性降低(P<0.05)。结论:阿托伐他汀联合肠溶阿司匹林可显著调节颈动脉粥样硬化患者炎性细胞因子,通过抑制炎症损伤,发挥抗颈动脉粥样硬化作用。

Objective： To observe the influence of atorvastatin combining with enteric-coated aspirin on serum tumor necrosis factor α（TNF-α） and interleukin-cell 6（IL-6） levels in patients with carotid atherosclerosis.Methods： A total of 125 patients with carotid atherosclerosis were randomly assigned to treatment group（64 cases） and control group（61 cases）,which were treated with atorvastatin combining with enteric-coated aspirin and atorvastatin alone separately.Six months after the treatment,compared the progress of atherosclerosis and TNF-α,IL-6 levels between the two groups.Results： After treatment,perimeters including the average carotid plaque volume,carotid artery lumen diameter,mean patch size and serum TNF-α,IL-6 levels were significantly decreased in both groups（P0.01）;which was more obviously in the treatment group except for the carotid artery lumen diameter（P0.05）.Conclusion： Atorvastatin combining with enteric-coated aspirin can significantly inhibit the progress of carotid atherosclerosis by adjusting inflammatory cytokine levels and suppressing inflammatory injuries.